Diabetes screening after gestational diabetes in England: A quantitative retrospective cohort study
The company rolled out Acomplia in 2006 following approval by the EMA, but the regulatory agency soon withdrew its nod due to an increased number of psychological disorders that were associated with the drug
GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review
Animal Model:Male A/J mice, lung carcinogenesis model [2] Dosage:1.3, 20.7, or 481 g/L Administration:Inhalation exposure, 45 min daily for 2 weeks Result:Reduced the tumor multiplicity
The main factor in the development of vasospasm is the clot residues around the arterial structures
Staff follow hygiene rules, and allergens are handled with care